Recently, the global market is still shrouded in the downturn and sluggish environment brought about by the economic crisis. World trade is in a slow recovery period. During this period, the production and export of pharmaceutical raw materials in China also encountered many difficulties, and many products showed a situation where volume, price, or volume fell. However, erythromycin thiocyanate has shown remarkable performance. In recent years, both the domestic market and foreign trade and exports have shown an upward trend in volume and price, and there are cases in which demand exceeds supply.
Under the background of the global economic downturn, why is the erythromycin thiocyanate bulk drug market in China able to maintain a strong trend and what will its future market trend be? Concern.
Asia, Africa and Latin America as the main battlefield For many years, China's erythromycin thiocyanate API has been mainly exported to overseas markets, especially since the 21st century, erythromycin thiocyanate exports have grown rapidly, has now developed into China's largest The largest exporter of cyclic lactone antibiotics, exports account for about 55% of the total domestic macrolide drugs. In 2003, China produced a total of 900 tons of erythromycin thiocyanate, of which 560 tons were exported, accounting for about 62% of the current year's output; in 2004, China produced a total of 1,180 tons of erythromycin thiocyanate, of which 620 tons were exported, the export amount 32% increase over the previous year. In 2006, the amount of erythromycin thiocyanate exported from China exceeded 1000 tons for the first time, reaching 1,172 tons, accounting for nearly 30% of the total export of macrolide antibiotics. By 2007, China's production capacity of erythromycin thiocyanate has exceeded 9,000 tons, with an output of more than 2,500 tons and an export volume of more than 1,500 tons. Now, our annual export of erythromycin thiocyanate has reached more than 3,000 tons.
The erythromycin thiocyanate exported from China is mostly used as a feed additive, because the production cost of our products is higher than that of foreign companies such as DSM in the Netherlands and Hearst in Germany, and these countries set higher levels of antibiotics for Chinese exports. The "threshold", therefore, less domestic erythromycin thiocyanate exports to the Western market. In the past few years, erythromycin thiocyanate in China has mainly been exported to Asia, Africa, Latin America and other places, accounting for about 80% of the total export volume of the product, and the remaining exports to the European Union and other developed countries.
Over the years, erythromycin thiocyanate exported by China to India, Malaysia and other Southeast Asian countries accounted for a large part of the export volume of this product. Among the exporting countries, India is the country's largest exporter, accounting for about 70% of the total, followed by Malaysia, Saudi Arabia and Jordan. In recent years, Brazil in South America has increased the demand for erythromycin thiocyanate in China. The relevant agencies predict that it will become another important foreign trade market for erythromycin thiocyanate in the future.
Prices are on a rising trend According to relevant market surveys, in 2009 and 2010, the export of erythromycin thiocyanate increased by 18% and 25% respectively year-on-year, becoming a higher increment of similar antibiotics. At the same time, prices in its domestic market are also rising, rising from RMB 300 per kilogram in 2009 to RMB 450 per kilogram in 2010 and rising to RMB 530 per kilogram in 2011. Export quotation also rose simultaneously to 67-68 US dollars / billion units. With the rising prices of products, there are times when the market is in short supply.
In the pharmaceutical enterprises for the export of erythromycin thiocyanate in China, Ningxia Qiyuan Pharmaceutical has been the No. 1 position for many years. Its export share accounts for about 50% of similar products in the country, and Yidu Dongsun Biochemical Pharmaceuticals ranked second. About 15%, Henan Huaxing Pharmaceutical accounted for about 10%. In recent years, the share of Yidu Dongsun Biochemical Pharmaceutical has slightly decreased, mainly because the company has converted its products to produce downstream products and then exported overseas.
In addition, erythromycin thiocyanate is the parent nucleus for the production of macrolide drug substances, and is a highly popular semi-synthetic erythromycin for synthesis of international pharmaceuticals market: erythromycin ethylsuccinate, azithromycin, roxithromycin The key intermediates of clarithromycin have an irreplaceable effect.
Due to the special "double identity" of erythromycin thiocyanate, it has established its strong position in the international pharmaceutical raw material drug market.
In recent years, erythromycin thiocyanate has not only enjoyed an excellent export situation, but has also become stronger in the domestic market, and its product sales are heating up. In the past, mainly export-oriented, and now gradually transformed into the same hot domestic and foreign markets. The main reason is that, in the domestic hospital drug market, several semi-synthetic erythromycin products such as azithromycin, roxithromycin, clarithromycin, and erythrosin ethylsuccinate are favored by the clinical practice. In the rapid increase, they currently occupy about 90% of macrolides.
As a basic raw material for the synthesis of these erythromycin products, the market demand for erythromycin thiocyanate is very strong. Although the volume of exports is still growing, due to the increase in the domestic market, the share of exports in total output is rapidly declining. In other words, the increase in demand for veterinary drugs and human drugs has become the main driving force for the rapid warming of the erythromycin thiocyanate market.
Emerging markets are worth looking forward to. According to analysis, the reason why the market for erythromycin thiocyanate is hot has been mainly due to strong domestic and international demand and insufficient supply of production.
In terms of demand, erythromycin thiocyanate has been widely used as a feed additive and “animal growth promoter†abroad for many years. In recent years, the economies of China, India, Brazil, Russia and other emerging countries have maintained a relatively rapid growth rate, and the people’s living standards have continued to increase. The demand for poultry, meat and eggs has been very rigid. Such a huge market continues to promote the rapid development of the aquaculture industry, and the demand for feed antibiotics and additives is enormous.
Over the years, India is China’s largest exporter of erythromycin thiocyanate, which generally accounts for about 70% of the share. In recent years, Brazil’s demand has soared rapidly and is expected to become another erythromycin thiocyanate in China. Important market.
In recent years, the growth rate of the breeding industry in Brazil has been rapid, and the demand for feed additives such as erythromycin thiocyanate has also increased year by year. Brazil now imports nearly one billion U.S. dollars worth of veterinary antibiotics and feed additives every year. The demand for feed additives including tetracycline hydrochloride, tylosin and erythromycin thiocyanate has increased year by year, with thiocyanate increasing. Erythromycin accounts for a considerable proportion.
In recent years, sales of macrolide antibiotics led by the third generation of erythromycin (azithromycin, clarithromycin, roxithromycin, etc.) have steadily increased in the international market, and their market share has also been expanding. , has risen from 5% in 2000 to 12% in 2010.
Demand for erythromycin thiocyanate is equally strong in the domestic market. Recently, the Chinese government has paid more and more attention to the people’s livelihood project, and the basic medical insurance work has achieved rapid progress. Whether it is the medical insurance for employees, the medical insurance for urban residents or the “New Rural Cooperativesâ€, whether it is coverage or protection level, there has been a great deal of improve. The demand for clinical first-line antibiotics such as azithromycin, roxithromycin, and clarithromycin in the medical market shows a trend of steadily increasing year by year. As the basic raw material, erythromycin thiocyanate, the demand of enterprises has been rising. Compared with export products, the domestic price of erythromycin thiocyanate products is tens of dollars higher per kilogram, making them more willing to sell their products domestically, which also caused the export volume to be insufficient for a period of time.
Although the development prospects of erythromycin thiocyanate in the domestic and foreign markets are very promising, but in the future what is the market trend, in addition to other various factors, the main depends on the scale of expansion of erythromycin API manufacturers in the end If the scale increases a lot, products are flooding into the market, showing a situation where supply exceeds demand, price wars are inevitable, and market trends will be highly uncertain. In addition, in the future, while expanding production capacity and production, Chinese enterprises should also pay attention to solving environmental problems, balance investment and efficiency issues, further improve product quality, strive to enter high-end markets such as Europe and America as soon as possible, and strive to make the entire industry more healthy and coordinated. And sustainable development.
Under the background of the global economic downturn, why is the erythromycin thiocyanate bulk drug market in China able to maintain a strong trend and what will its future market trend be? Concern.
Asia, Africa and Latin America as the main battlefield For many years, China's erythromycin thiocyanate API has been mainly exported to overseas markets, especially since the 21st century, erythromycin thiocyanate exports have grown rapidly, has now developed into China's largest The largest exporter of cyclic lactone antibiotics, exports account for about 55% of the total domestic macrolide drugs. In 2003, China produced a total of 900 tons of erythromycin thiocyanate, of which 560 tons were exported, accounting for about 62% of the current year's output; in 2004, China produced a total of 1,180 tons of erythromycin thiocyanate, of which 620 tons were exported, the export amount 32% increase over the previous year. In 2006, the amount of erythromycin thiocyanate exported from China exceeded 1000 tons for the first time, reaching 1,172 tons, accounting for nearly 30% of the total export of macrolide antibiotics. By 2007, China's production capacity of erythromycin thiocyanate has exceeded 9,000 tons, with an output of more than 2,500 tons and an export volume of more than 1,500 tons. Now, our annual export of erythromycin thiocyanate has reached more than 3,000 tons.
The erythromycin thiocyanate exported from China is mostly used as a feed additive, because the production cost of our products is higher than that of foreign companies such as DSM in the Netherlands and Hearst in Germany, and these countries set higher levels of antibiotics for Chinese exports. The "threshold", therefore, less domestic erythromycin thiocyanate exports to the Western market. In the past few years, erythromycin thiocyanate in China has mainly been exported to Asia, Africa, Latin America and other places, accounting for about 80% of the total export volume of the product, and the remaining exports to the European Union and other developed countries.
Over the years, erythromycin thiocyanate exported by China to India, Malaysia and other Southeast Asian countries accounted for a large part of the export volume of this product. Among the exporting countries, India is the country's largest exporter, accounting for about 70% of the total, followed by Malaysia, Saudi Arabia and Jordan. In recent years, Brazil in South America has increased the demand for erythromycin thiocyanate in China. The relevant agencies predict that it will become another important foreign trade market for erythromycin thiocyanate in the future.
Prices are on a rising trend According to relevant market surveys, in 2009 and 2010, the export of erythromycin thiocyanate increased by 18% and 25% respectively year-on-year, becoming a higher increment of similar antibiotics. At the same time, prices in its domestic market are also rising, rising from RMB 300 per kilogram in 2009 to RMB 450 per kilogram in 2010 and rising to RMB 530 per kilogram in 2011. Export quotation also rose simultaneously to 67-68 US dollars / billion units. With the rising prices of products, there are times when the market is in short supply.
In the pharmaceutical enterprises for the export of erythromycin thiocyanate in China, Ningxia Qiyuan Pharmaceutical has been the No. 1 position for many years. Its export share accounts for about 50% of similar products in the country, and Yidu Dongsun Biochemical Pharmaceuticals ranked second. About 15%, Henan Huaxing Pharmaceutical accounted for about 10%. In recent years, the share of Yidu Dongsun Biochemical Pharmaceutical has slightly decreased, mainly because the company has converted its products to produce downstream products and then exported overseas.
In addition, erythromycin thiocyanate is the parent nucleus for the production of macrolide drug substances, and is a highly popular semi-synthetic erythromycin for synthesis of international pharmaceuticals market: erythromycin ethylsuccinate, azithromycin, roxithromycin The key intermediates of clarithromycin have an irreplaceable effect.
Due to the special "double identity" of erythromycin thiocyanate, it has established its strong position in the international pharmaceutical raw material drug market.
In recent years, erythromycin thiocyanate has not only enjoyed an excellent export situation, but has also become stronger in the domestic market, and its product sales are heating up. In the past, mainly export-oriented, and now gradually transformed into the same hot domestic and foreign markets. The main reason is that, in the domestic hospital drug market, several semi-synthetic erythromycin products such as azithromycin, roxithromycin, clarithromycin, and erythrosin ethylsuccinate are favored by the clinical practice. In the rapid increase, they currently occupy about 90% of macrolides.
As a basic raw material for the synthesis of these erythromycin products, the market demand for erythromycin thiocyanate is very strong. Although the volume of exports is still growing, due to the increase in the domestic market, the share of exports in total output is rapidly declining. In other words, the increase in demand for veterinary drugs and human drugs has become the main driving force for the rapid warming of the erythromycin thiocyanate market.
Emerging markets are worth looking forward to. According to analysis, the reason why the market for erythromycin thiocyanate is hot has been mainly due to strong domestic and international demand and insufficient supply of production.
In terms of demand, erythromycin thiocyanate has been widely used as a feed additive and “animal growth promoter†abroad for many years. In recent years, the economies of China, India, Brazil, Russia and other emerging countries have maintained a relatively rapid growth rate, and the people’s living standards have continued to increase. The demand for poultry, meat and eggs has been very rigid. Such a huge market continues to promote the rapid development of the aquaculture industry, and the demand for feed antibiotics and additives is enormous.
Over the years, India is China’s largest exporter of erythromycin thiocyanate, which generally accounts for about 70% of the share. In recent years, Brazil’s demand has soared rapidly and is expected to become another erythromycin thiocyanate in China. Important market.
In recent years, the growth rate of the breeding industry in Brazil has been rapid, and the demand for feed additives such as erythromycin thiocyanate has also increased year by year. Brazil now imports nearly one billion U.S. dollars worth of veterinary antibiotics and feed additives every year. The demand for feed additives including tetracycline hydrochloride, tylosin and erythromycin thiocyanate has increased year by year, with thiocyanate increasing. Erythromycin accounts for a considerable proportion.
In recent years, sales of macrolide antibiotics led by the third generation of erythromycin (azithromycin, clarithromycin, roxithromycin, etc.) have steadily increased in the international market, and their market share has also been expanding. , has risen from 5% in 2000 to 12% in 2010.
Demand for erythromycin thiocyanate is equally strong in the domestic market. Recently, the Chinese government has paid more and more attention to the people’s livelihood project, and the basic medical insurance work has achieved rapid progress. Whether it is the medical insurance for employees, the medical insurance for urban residents or the “New Rural Cooperativesâ€, whether it is coverage or protection level, there has been a great deal of improve. The demand for clinical first-line antibiotics such as azithromycin, roxithromycin, and clarithromycin in the medical market shows a trend of steadily increasing year by year. As the basic raw material, erythromycin thiocyanate, the demand of enterprises has been rising. Compared with export products, the domestic price of erythromycin thiocyanate products is tens of dollars higher per kilogram, making them more willing to sell their products domestically, which also caused the export volume to be insufficient for a period of time.
Although the development prospects of erythromycin thiocyanate in the domestic and foreign markets are very promising, but in the future what is the market trend, in addition to other various factors, the main depends on the scale of expansion of erythromycin API manufacturers in the end If the scale increases a lot, products are flooding into the market, showing a situation where supply exceeds demand, price wars are inevitable, and market trends will be highly uncertain. In addition, in the future, while expanding production capacity and production, Chinese enterprises should also pay attention to solving environmental problems, balance investment and efficiency issues, further improve product quality, strive to enter high-end markets such as Europe and America as soon as possible, and strive to make the entire industry more healthy and coordinated. And sustainable development.
There are a variety of lock cores and suitable for different countries. The lock core is used for door locks. Different locks are suitable for different lock cores. We specialize in the production of American brass lock core. Can accept customer demand customization. Can accept a variety of keyway requirements.
Profile Cylinders
Mortise Cylinders
Mortise T-Turn Cylinders
Mortise Dummy Cylinders
Rim Cylinders
Rim Dummy Cylinders
Knob/Lever Cylinders
Small Format IC Core
Large Format IC Cores
Sfic Lock Cylinder,Removable Cylinder Lock,Master Key Lock Cylinder,Zinc Alloy Lock Cylinder
ANDJA TRADING PET. LTD. , https://www.lock-cylinder.com